drugset / Trial / NCT04723030
The Transformation of Locally Advanced Pancreatic Cancer.
NaSingle-groupOpen-labelTreatment
Summary
This trial will explore the efficacy and safety of camrelizumab combined with apatinib mesylate and radiotherapy and chemotherapy (paclitaxel (albumin binding) combined with gemcitabine and cisplatin) in the treatment of locally advanced pancreatic cancer in patients with locally advanced pancreatic cancer.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2023-04-01
- Completion
- 2023-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |